drugset / Trial / NCT00913666

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

NCT00913666

Phase 4 Completed 121 enrolled Biogen
Non-randomizedParallel-groupSingle-blindBasic science

Summary

This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.

Timeline

Start
2002-11
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular

Indications